FBIO Quote, Financials, Valuation and Earnings

Lyell Immunopharma, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of -258973.33%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 208.91%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 37.35%. Given that Fortress Biotech, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Lyell Immunopharma, Inc..

Fortress Biotech, Inc. has a beta of 1.433, which suggesting that the stock is 43.28% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are larger than Lyell Immunopharma, Inc. quarterly revenues of $15K. Fortress Biotech, Inc.'s net income of $8.8M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.64x versus 78,326.03x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of -121.83%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Moderna, Inc.'s return on equity of -29.19%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 208.91%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16%. Given that Fortress Biotech, Inc. has higher upside potential than Moderna, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Moderna, Inc..

Fortress Biotech, Inc. has a beta of 1.433, which suggesting that the stock is 43.28% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Fortress Biotech, Inc.'s net income of $8.8M is higher than Moderna, Inc.'s net income of -$826M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.64x versus 9.95x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of -382.1%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 208.91%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 2.52%. Given that Fortress Biotech, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Fortress Biotech, Inc. has a beta of 1.433, which suggesting that the stock is 43.28% more volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.89% to investors and pays a quarterly dividend of $0.25 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Fortress Biotech, Inc.'s net income of $8.8M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.64x versus 65.99x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of 36.91%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 208.91%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.70 which suggests that it could grow by 13.09%. Given that Fortress Biotech, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Fortress Biotech, Inc. has a beta of 1.433, which suggesting that the stock is 43.28% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Fortress Biotech, Inc.'s net income of $8.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 30.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.64x versus 10.03x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.